Filtered By:
Drug: Aspirin
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 3663 results found since Jan 2013.
Recombinant tissue-type plasminogen activator (rt-PA) effectively restores neurological function and improves prognosis in acute ischemic stroke
CONCLUSION: Compared with conventional pharmacological regimens, additional rt-PA intravenous thrombolytic therapy improves the clinical outcome of patients with acute ischemic stroke, promotes neurological recovery, and enhances patient prognosis without increasing the risk of patient-related adverse events.PMID:37303683 | PMC:PMC10251022
Source: American Journal of Translational Research - June 12, 2023 Category: Research Authors: Shouyun Zhang Dezhen Wang Lin Li Source Type: research
P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial
EuroIntervention. 2023 Jun 12:EIJ-D-23-00125. doi: 10.4244/EIJ-D-23-00125. Online ahead of print.ABSTRACTDual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary intervention (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single antiplatelet therapy (SAPT) strategy with a potent P2Y12 inhibitor is safe and associated with less bleeding. However, to date, no randomised trial has tested the impact of initiating SAPT immediately after PCI, particularly in patients with acute coronary syndromes (ACS). NEOMINDSET is a multicentre, randomised, open...
Source: EuroIntervention - June 12, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Patricia O Guimar ães Marcelo Franken Caio A M Tavares Fabio S Silveira Murillo O Antunes Ricardo R Bergo Rodrigo M Joaquim Jessica C S Hirai Pedro B Andrade Fabio G Pitta Jos é Mariani Bruno R Nascimento Jo ão E T de Paula Marcos S Silveira Tiberio A Source Type: research
Recombinant tissue-type plasminogen activator (rt-PA) effectively restores neurological function and improves prognosis in acute ischemic stroke
CONCLUSION: Compared with conventional pharmacological regimens, additional rt-PA intravenous thrombolytic therapy improves the clinical outcome of patients with acute ischemic stroke, promotes neurological recovery, and enhances patient prognosis without increasing the risk of patient-related adverse events.PMID:37303683 | PMC:PMC10251022
Source: American Journal of Translational Research - June 12, 2023 Category: Research Authors: Shouyun Zhang Dezhen Wang Lin Li Source Type: research
P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial
EuroIntervention. 2023 Jun 12:EIJ-D-23-00125. doi: 10.4244/EIJ-D-23-00125. Online ahead of print.ABSTRACTDual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary intervention (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single antiplatelet therapy (SAPT) strategy with a potent P2Y12 inhibitor is safe and associated with less bleeding. However, to date, no randomised trial has tested the impact of initiating SAPT immediately after PCI, particularly in patients with acute coronary syndromes (ACS). NEOMINDSET is a multicentre, randomised, open...
Source: EuroIntervention - June 12, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Patricia O Guimar ães Marcelo Franken Caio A M Tavares Fabio S Silveira Murillo O Antunes Ricardo R Bergo Rodrigo M Joaquim Jessica C S Hirai Pedro B Andrade Fabio G Pitta Jos é Mariani Bruno R Nascimento Jo ão E T de Paula Marcos S Silveira Tiberio A Source Type: research
Recombinant tissue-type plasminogen activator (rt-PA) effectively restores neurological function and improves prognosis in acute ischemic stroke
CONCLUSION: Compared with conventional pharmacological regimens, additional rt-PA intravenous thrombolytic therapy improves the clinical outcome of patients with acute ischemic stroke, promotes neurological recovery, and enhances patient prognosis without increasing the risk of patient-related adverse events.PMID:37303683 | PMC:PMC10251022
Source: American Journal of Translational Research - June 12, 2023 Category: Research Authors: Shouyun Zhang Dezhen Wang Lin Li Source Type: research
